InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,626.02
(
0.54%
)
US TECH 100
18,986.40
(
0.30%
)
Dow Jones
41,393.78
(
0.72%
)
Brent Oil
71.83
(
0.00%
)
Bitcoin
59,714.50
(
-1.43%
)
Post# of 253120
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120432
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ThomasS post# 100393

Monday, 08/02/2010 8:44:34 AM

Monday, August 02, 2010 8:44:34 AM

Post# of 253120
Re: MNTA milestone payments

If I’m reading this correctly, the $5M MNTA will receive from NVS for FDA approval of generic Lovenox is separate from the $163M in potential milestones MNTA can earn from NVS for regulatory and sales milestones pertaining to Copaxone in all jurisdictions and Lovenox in the EU. (The $5M milestone comes from NVS-MNTA’s 2003 agreement, while the $163M comes from the companies’ 2006 agreement.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up